Form 4: Maze Therapeutics Executive Trades Shares

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, reported transactions involving common stock and stock options on July 1, 2026.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, engaged in several stock transactions on July 1, 2026.
• These transactions included the acquisition of 14,609 shares of common stock at $10.42 per share, executed under a Rule 10b5-1 trading plan.
• Additionally, Bernstein disposed of 13,409 shares at a weighted average price of $29.865 and 1,200 shares at a weighted average price of $30.3369.
• Following these transactions, Bernstein beneficially owns 1,200 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a key executive, despite the use of a Rule 10b5-1 plan.

Positives

• The acquisition of 14,609 shares at $10.42 per share indicates continued investment or alignment with the company's stock value.
• The transactions were executed under a Rule 10b5-1 trading plan, suggesting pre-planned and potentially less market-sensitive trading activity.

Negatives

• The disposal of a significant number of shares (14,609 shares) by a key executive could be perceived negatively by the market.
• The sale of shares at prices significantly higher than the acquisition price ($29.865 and $30.3369 vs. $10.42) represents a substantial profit-taking event for the executive.

Risks

• The disposal of shares by a high-ranking executive might signal a lack of confidence in future price appreciation, although executed under a 10b5-1 plan.
• The weighted average sale prices indicate a range of selling prices, which could be subject to further scrutiny if specific price points are of concern.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
• The reported prices for disposed shares are weighted averages, with specific ranges provided for further information upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a senior executive like Harold Bernstein at Maze Therapeutics is common practice to diversify holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders may interpret the sale of shares by a senior executive as a potential signal of reduced confidence, although the Rule 10b5-1 plan mitigates this concern to some extent.
• Employees may also observe executive trading patterns as an indicator of company performance and future prospects.

Next Steps

• The reporting person will provide full information regarding the number of shares sold at each separate price within the specified ranges upon request from the Issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established plan. While the sale of shares by a key executive warrants attention, the structured nature of the trades via a Rule 10b5-1 plan suggests it's not necessarily a reflection of negative future outlook. Therefore, a 'hold' recommendation is appropriate, pending further company-specific developments.

Keywords

Form 4, SEC Filing, Maze Therapeutics, Harold Bernstein, Stock Transaction, Insider Trading, Rule 10b5-1, Common Stock, Stock Options, Beneficial Ownership